“…For these reasons, major efforts have been expended on identifying retinoids that are selective for one of the three RAR subtypes in the effort to improve therapeutic indices by eliminating any of the adverse reactions that would be caused by the other subtypes [14,15,17,[62][63][64][65]. This strategy was considered feasible because of the diversity in the retinoid response pathways with the RAR subtypes functioning as heterodimers with the RXR subtypes [7][8][9][10], complexing with various modulatory proteins (transcriptional coactivators and corepressors) [9,66], binding to various responsive elements (REs) in the promoter regions of retinoid-modulated genes [10,67], and having tissue distribution patterns that varied with cell type and differentiation state [68][69][70][71][72][73][74][75]. Generally, in normal epithelial cells, from which many cancers arise, only RARα and RARγ are expressed or predominate [72,73], whereas RARβ is absent or present at very low levels [72,75].…”